​
​

Enanta Pharmaceuticals (ENTA) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ENTA Stock Forecast

Enanta Pharmaceuticals stock forecast is as follows: an average price target of $65.67 (represents a 586.21% upside from ENTA’s last price of $9.57) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.

ENTA Price Target

The average price target for Enanta Pharmaceuticals (ENTA) is $65.67 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $87.00 to $54.00. This represents a potential 586.21% upside from ENTA's last price of $9.57.

ENTA Analyst Ratings

Buy

According to 4 Wall Street analysts, Enanta Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for ENTA stock is 0 'Strong Buy' (0.00%), 3 'Buy' (75.00%), 1 'Hold' (25.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Enanta Pharmaceuticals Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 09, 2022-H.C. Wainwright$56.00$41.9633.46%485.16%
Nov 22, 2022-RBC Capital$54.00$46.4016.38%464.26%
Jul 29, 2022Yasmeen RahimiPiper Sandler$87.00$51.2769.67%809.09%
Row per page
Go to

The latest Enanta Pharmaceuticals stock forecast, released on Dec 09, 2022 by H.C. Wainwright company, set a price target of $56.00, which represents a 33.46% increase from the stock price at the time of the forecast ($41.96), and a 485.16% increase from ENTA last price ($9.57).

Enanta Pharmaceuticals Price Target by Period

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$9.57$9.57$9.57
Upside/Downside-100.00%-100.00%-100.00%

In the current month, the average price target of Enanta Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Enanta Pharmaceuticals's last price of $9.57. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Oct 09, 2024JMP SecuritiesMarket OutperformMarket OutperformHold
Feb 08, 2023Piper SandlerOverweightOverweightHold
Nov 22, 2022RBC CapitalSector PerformSector PerformHold
Jul 29, 2022Piper SandlerOverweightOverweightHold
Jul 06, 2022Evercore ISI-OutperformUpgrade
Row per page
Go to

Enanta Pharmaceuticals's last stock rating was published by JMP Securities on Oct 09, 2024. The company gave ENTA a "Market Outperform" rating, the same as its previous rate.

Enanta Pharmaceuticals Financial Forecast

Enanta Pharmaceuticals Revenue Forecast

Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17Mar 16
Revenue-------$18.00M$18.93M$18.89M$17.80M$23.59M$20.32M$19.48M$18.72M$27.65M$23.57M$21.62M$20.13M$31.74M$23.63M$18.65M$27.62M$52.57M$51.31M$44.37M$39.63M$44.05M$8.96M$13.00M
Avg Forecast$16.43M$16.08M$16.23M$18.90M$17.99M$17.44M$16.09M$21.95M$17.49M$18.19M$19.04M$23.55M$23.13M$20.65M$20.67M$27.37M$26.34M$21.86M$24.38M$27.73M$25.55M$26.32M$30.05M$58.07M$55.94M$46.98M$40.88M$38.27M$12.16M$14.44M
High Forecast$16.43M$16.08M$16.23M$18.90M$18.94M$17.44M$16.09M$22.75M$33.07M$18.19M$19.04M$23.55M$23.13M$20.65M$20.67M$27.37M$26.34M$21.86M$24.38M$27.73M$25.55M$26.32M$30.05M$58.07M$55.94M$46.98M$40.88M$45.93M$14.59M$17.33M
Low Forecast$16.43M$16.08M$16.23M$18.90M$17.47M$17.44M$16.09M$21.13M$7.85M$18.19M$19.04M$23.55M$23.13M$20.65M$20.67M$27.37M$26.34M$21.86M$24.38M$27.73M$25.55M$26.32M$30.05M$58.07M$55.94M$46.98M$40.88M$30.62M$9.73M$11.56M
# Analysts33345412763222234566454434381110
Surprise %-------0.82%1.08%1.04%0.93%1.00%0.88%0.94%0.91%1.01%0.90%0.99%0.83%1.14%0.92%0.71%0.92%0.91%0.92%0.94%0.97%1.15%0.74%0.90%

Enanta Pharmaceuticals's average Quarter revenue forecast for Mar 24 based on 1 analysts is $16.09M, with a low forecast of $16.09M, and a high forecast of $16.09M. ENTA's average Quarter revenue forecast represents a -10.61% decrease compared to the company's last Quarter revenue of $18.00M (Dec 23).

Enanta Pharmaceuticals EBITDA Forecast

Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17Mar 16
# Analysts33345412763222234566454434381110
EBITDA-------$-29.95M$-25.70M$-36.71M$-39.45M$-30.01M$-26.39M$-31.82M$-33.02M$-29.37M$-32.59M$-32.59M$-27.78M$-10.75M$-17.73M$-20.49M$-7.06M$17.93M$9.60M$7.05M$1.74M$18.54M$-8.42M$351.00K
Avg Forecast$-10.23M$-10.02M$-10.11M$-11.77M$-11.21M$-10.87M$-45.11M$-13.67M$-10.90M$-11.34M$-35.66M$-22.30M$-14.62M$-13.06M$-28.19M$-17.30M$-16.65M$-13.82M$-24.66M$-17.53M$-16.15M$-16.64M$-10.57M$-36.71M$-35.37M$-29.70M$7.06M$15.74M$-10.64M$916.11K
High Forecast$-10.23M$-10.02M$-10.11M$-11.77M$-10.88M$-10.87M$-36.08M$-13.17M$-4.89M$-11.34M$-28.53M$-17.84M$-14.62M$-13.06M$-22.55M$-17.30M$-16.65M$-13.82M$-19.73M$-17.53M$-16.15M$-16.64M$-8.45M$-36.71M$-35.37M$-29.70M$8.47M$18.89M$-8.51M$1.10M
Low Forecast$-10.23M$-10.02M$-10.11M$-11.77M$-11.80M$-10.87M$-54.13M$-14.18M$-20.61M$-11.34M$-42.79M$-26.76M$-14.62M$-13.06M$-33.82M$-17.30M$-16.65M$-13.82M$-29.59M$-17.53M$-16.15M$-16.64M$-12.68M$-36.71M$-35.37M$-29.70M$5.65M$12.59M$-12.76M$732.89K
Surprise %-------2.19%2.36%3.24%1.11%1.35%1.81%2.44%1.17%1.70%1.96%2.36%1.13%0.61%1.10%1.23%0.67%-0.49%-0.27%-0.24%0.25%1.18%0.79%0.38%

4 analysts predict ENTA's average Quarter EBITDA for Mar 20 to be $-10.57M, with a high of $-8.45M and a low of $-12.68M. This is -158.94% lower than Enanta Pharmaceuticals's previous annual EBITDA (Dec 19) of $17.93M.

Enanta Pharmaceuticals Net Income Forecast

Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17Mar 16
# Analysts33345412763222234566454434381110
Net Income-------$-33.41M$-28.11M$-39.06M$-37.66M$-28.99M$-26.35M$-31.70M$-33.34M$-30.11M$-24.60M$-24.02M$-22.05M$-8.33M$-29.34M$-14.27M$-6.00M$13.44M$9.19M$7.04M$4.14M$12.55M$-5.39M$-1.65M
Avg Forecast$-30.61M$-29.55M$-27.96M$-23.19M$-24.59M$-30.34M$-46.24M$-25.97M$-44.99M$-47.62M$-36.55M$-22.87M$-26.52M$-29.43M$-28.89M$-23.35M$-25.65M$-27.87M$-19.57M$-16.24M$-18.90M$-17.90M$-8.99M$11.57M$11.20M$3.45M$16.79M$10.66M$-6.81M$-4.29M
High Forecast$-30.61M$-29.55M$-27.96M$-23.19M$-14.84M$-30.34M$-36.99M$-23.55M$-25.87M$-47.62M$-29.24M$-18.29M$-26.52M$-29.43M$-23.12M$-23.35M$-25.65M$-27.87M$-15.66M$-16.24M$-18.90M$-17.90M$-7.19M$11.57M$11.20M$3.45M$20.14M$12.79M$-5.45M$-3.43M
Low Forecast$-30.61M$-29.55M$-27.96M$-23.19M$-31.80M$-30.34M$-55.48M$-29.71M$-52.87M$-47.62M$-43.86M$-27.44M$-26.52M$-29.43M$-34.67M$-23.35M$-25.65M$-27.87M$-23.48M$-16.24M$-18.90M$-17.90M$-10.78M$11.57M$11.20M$3.45M$13.43M$8.53M$-8.17M$-5.15M
Surprise %-------1.29%0.62%0.82%1.03%1.27%0.99%1.08%1.15%1.29%0.96%0.86%1.13%0.51%1.55%0.80%0.67%1.16%0.82%2.04%0.25%1.18%0.79%0.38%

Enanta Pharmaceuticals's average Quarter net income forecast for Mar 20 is $-8.99M, with a range of $-10.78M to $-7.19M. ENTA's average Quarter net income forecast represents a -166.85% decrease compared to the company's last Quarter net income of $13.44M (Dec 19).

Enanta Pharmaceuticals SG&A Forecast

Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17Mar 16
# Analysts33345412763222234566454434381110
SG&A-------$16.52M$13.79M$12.62M$13.78M$12.70M$12.57M$12.93M$10.48M$9.51M$8.36M$8.48M$8.33M$7.38M$6.73M$6.82M$6.88M$6.92M$6.16M$6.15M$6.78M$5.71M$5.46M$4.43M
Avg Forecast$6.18M$6.05M$6.11M$7.11M$6.77M$6.57M$14.42M$8.26M$6.58M$6.85M$11.40M$7.22M$8.71M$7.77M$9.01M$10.30M$9.91M$8.23M$7.39M$10.44M$9.62M$9.91M$10.30M$21.86M$21.06M$17.68M$27.46M$4.84M$6.90M$11.55M
High Forecast$6.18M$6.05M$6.11M$7.11M$7.13M$6.57M$17.30M$8.56M$12.45M$6.85M$13.68M$8.66M$8.71M$7.77M$10.81M$10.30M$9.91M$8.23M$8.87M$10.44M$9.62M$9.91M$12.36M$21.86M$21.06M$17.68M$32.95M$5.81M$8.28M$13.86M
Low Forecast$6.18M$6.05M$6.11M$7.11M$6.57M$6.57M$11.54M$7.95M$2.95M$6.85M$9.12M$5.78M$8.71M$7.77M$7.21M$10.30M$9.91M$8.23M$5.91M$10.44M$9.62M$9.91M$8.24M$21.86M$21.06M$17.68M$21.97M$3.88M$5.52M$9.24M
Surprise %-------2.00%2.10%1.84%1.21%1.76%1.44%1.66%1.16%0.92%0.84%1.03%1.13%0.71%0.70%0.69%0.67%0.32%0.29%0.35%0.25%1.18%0.79%0.38%

Enanta Pharmaceuticals's average Quarter SG&A projection for Mar 24 is $14.42M, based on 1 Wall Street analysts, with a range of $11.54M to $17.30M. The forecast indicates a -12.71% fall compared to ENTA last annual SG&A of $16.52M (Dec 23).

Enanta Pharmaceuticals EPS Forecast

Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17Mar 16
# Analysts33345412763222234566454434381110
EPS-------$-1.58$-1.34$-1.86$-1.79$-1.39$-1.28$-1.53$-1.62$-1.48$-1.22$-1.19$-1.09$-0.41$-1.46$-0.71$-0.30$0.68$0.47$0.36$0.21$0.65$-0.28$-0.09
Avg Forecast$-1.45$-1.40$-1.32$-1.09$-1.16$-1.43$-1.34$-1.23$-2.12$-2.25$-1.96$-1.57$-1.25$-1.39$-1.42$-1.10$-1.21$-1.32$-0.98$-0.77$-0.89$-0.84$-0.75$0.55$0.53$0.16$-0.06$0.45$-0.48$0.26
High Forecast$-1.45$-1.40$-1.32$-1.09$-0.70$-1.43$-1.34$-1.11$-1.22$-2.25$-1.96$-1.57$-1.25$-1.39$-1.42$-1.10$-1.21$-1.32$-0.98$-0.77$-0.89$-0.84$-0.75$0.55$0.53$0.16$-0.06$0.54$-0.38$0.31
Low Forecast$-1.45$-1.40$-1.32$-1.09$-1.50$-1.43$-1.34$-1.40$-2.50$-2.25$-1.96$-1.57$-1.25$-1.39$-1.42$-1.10$-1.21$-1.32$-0.98$-0.77$-0.89$-0.84$-0.75$0.55$0.53$0.16$-0.06$0.36$-0.58$0.21
Surprise %-------1.29%0.63%0.83%0.91%0.88%1.02%1.10%1.14%1.34%1.01%0.90%1.11%0.53%1.64%0.84%0.40%1.24%0.89%2.21%-3.61%1.44%0.58%-0.35%

According to 4 Wall Street analysts, Enanta Pharmaceuticals's projected average Quarter EPS for Mar 20 is $-0.75, with a low estimate of $-0.75 and a high estimate of $-0.75. This represents a -210.50% decrease compared to ENTA previous annual EPS of $0.68 (Dec 19).

Enanta Pharmaceuticals Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
IPSCCentury Therapeutics$1.25$15.001100.00%Buy
HOWLWerewolf Therapeutics$1.71$12.00601.75%Buy
ENTAEnanta Pharmaceuticals$9.57$65.67586.21%Buy
LYELLyell Immunopharma$1.11$6.67500.90%Hold
CCCCC4 Therapeutics$4.20$13.50221.43%Buy
MLYSMineralys Therapeutics$11.40$30.00163.16%Buy
STOKStoke Therapeutics$11.88$30.60157.58%Buy
CGEMCullinan Oncology$13.45$31.50134.20%Buy
KRONKronos Bio$0.85$1.6391.76%Buy
MRUSMerus$44.27$77.1374.23%Buy
DSGNDesign Therapeutics$5.76$9.6767.88%Buy
EWTXEdgewise Therapeutics$30.79$45.0046.15%Buy
CRNXCrinetics Pharmaceuticals$53.70$70.1430.61%Buy
RVMDRevolution Medicines, Inc. Warrant$54.24$60.6311.78%Buy
IKNAIkena Oncology$1.68$1.33-20.83%Buy

ENTA Forecast FAQ

Is Enanta Pharmaceuticals a good buy?

Yes, according to 4 Wall Street analysts, Enanta Pharmaceuticals (ENTA) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 75.00% of ENTA's total ratings.

What is ENTA's price target?

Enanta Pharmaceuticals (ENTA) average price target is $65.67 with a range of $54 to $87, implying a 586.21% from its last price of $9.57. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Enanta Pharmaceuticals stock go up soon?

According to Wall Street analysts' prediction for ENTA stock, the company can go up by 586.21% (from the last price of $9.57 to the average price target of $65.67), up by 809.09% based on the highest stock price target, and up by 464.26% based on the lowest stock price target.

Can Enanta Pharmaceuticals stock reach $14?

ENTA's average twelve months analyst stock price target of $65.67 supports the claim that Enanta Pharmaceuticals can reach $14 in the near future.

What are Enanta Pharmaceuticals's analysts' financial forecasts?

Enanta Pharmaceuticals's analysts financial forecasts for the fiscal year (Sep 2024) are as follows: average revenue is $73.47M (high $75.23M, low $72.14M), average EBITDA is $-80.854M (high $-71.002M, low $-90.973M), average net income is $-127M (high $-106M, low $-147M), average SG&A $36.02M (high $39.56M, low $32.63M), and average EPS is $-5.156 (high $-4.581, low $-5.673). ENTA's analysts financial forecasts for the fiscal year (Sep 2025) are as follows: average revenue is $67.64M (high $67.64M, low $67.64M), average EBITDA is $-42.141M (high $-42.141M, low $-42.141M), average net income is $-111M (high $-111M, low $-111M), average SG&A $25.46M (high $25.46M, low $25.46M), and average EPS is $-5.255 (high $-5.255, low $-5.255).

Did the ENTA's actual financial results beat the analysts' financial forecasts?

Based on Enanta Pharmaceuticals's last annual report (Sep 2023), the company's revenue was $79.2M, beating the average analysts forecast of $78.28M by 1.18%. Apple's EBITDA was $-137M, beating the average prediction of $-80.191M by 71.10%. The company's net income was $-134M, missing the average estimation of $-152M by -11.98%. Apple's SG&A was $52.89M, beating the average forecast of $32.05M by 65.02%. Lastly, the company's EPS was $-6.38, missing the average prediction of $-7.909 by -19.33%. In terms of the last quarterly report (Dec 2023), Enanta Pharmaceuticals's revenue was $18M, missing the average analysts' forecast of $21.95M by -17.97%. The company's EBITDA was $-29.946M, beating the average prediction of $-13.674M by 119.00%. Enanta Pharmaceuticals's net income was $-33.407M, beating the average estimation of $-25.967M by 28.65%. The company's SG&A was $16.52M, beating the average forecast of $8.26M by 99.96%. Lastly, the company's EPS was $-1.58, beating the average prediction of $-1.226 by 28.87%